Please assess the completion status of the following clinical trial:

Trial Title: A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Men or women, at least 18 years of age, with evidence of moderate renal impairment (an eGFR ≥ 30 and \<60 mL/min/1.73 m2) and myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI).~Exclusion Criteria:~* Symptoms, biomarker elevation or electrocardiogram (ECG) changes other than those of the index event that are consistent with a diagnosis of AMI but are likely not due to primary myocardial ischemia~* Ongoing hemodynamic instability~* Planned coronary artery bypass surgery~* Evidence of hepatobiliary disease~* History of acute kidney injury (AKI) after previous exposure to an intravenous contrast agent.~* History of nephrotic range proteinuria.~* Known history of allergy to soy beans or peanuts, immunoglobulin A (IgA) deficiency, antibodies to IgA , or hypersensitivity to CSL112 or any of its components.~* Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CSL_112 (Type: EXPERIMENTAL): CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).